update... 2018-08-17 12:32 ET - News Release
Mr. Marcos Agramont reports
ISODIOL INTERNATIONAL INC. APPLAUDS THE WORLD HEALTH ORGANIZATION ON ITS RECOMMENDATION THAT PURE CBD SHOULD NOT BE SCHEDULED WITHIN INTERNATIONAL DRUG CONTROL CONVENTIONS
Isodiol International Inc. is applauding the World Health Organization's (WHO) historic recommendation (at the conference in Geneva) that pure CBD (cannabidiol) should not be scheduled within the international drug control conventions.
Some key findings from the WHO:
- The Kids Are All Right: "There are no case reports of abuse or dependence relating to the use of pure CBD."
- We Won't Get Fooled Again: "No public health problems have been associated with CBD use."
- You Better, You Bet: "CBD has been found to be generally well tolerated with a good safety profile."
- My Generation: "There is no evidence that CBD is liable to similar abuse and similar ill-effects as substances{A …}such as cannabis or THC."
"This historic announcement by the World Health Organization will bring the much-needed education to those still skeptical or uneducated on CBD and it should help to eliminate unnecessary road blocks around the world for commercializing pure, natural CBD in the food and supplement industry," said Marcos Agramont, Isodiol's CEO. "We believe this announcement will allow the Company to continue to fast track its international business expansion plans."
In the United States, passage of the 2018 Farm Bill with the Senate's pro-hemp language will ensure the full legalization of hemp extracts and derivatives. The Company strongly urges you to send an email to your Members of Congress today urging them to permanently legalize hemp and hemp-derived CBD.
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical-grade pure, natural CBD and in the manufacturing and development of CBD consumer products.
Isodiol is the pioneer of many firsts in the CBD industry, including the commercialization of 99%+ pure, natural isolated CBD, micro-encapsulations, and nano-technology for the highest quality topical skin care and consumable products. Most recently, the Company received approval for its highest grade CBD to be designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products, which was announced on April 26, 2018.
Isodiol's growth strategy includes the development of over-the-counter (OTC) and pharmaceutical drugs, expanding its consumer products portfolio, and aggressively continuing international expansion into Latin America, Asia, and Europe.